IR Overview
Cyclo Therapeutics, Inc. (Nasdaq: CYTH)Cyclo Therapeutics, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com The CTD division provides the world’s widest range of cyclodextrin-based fine chemicals available from a single source in both research and commercial quantities to life science laboratories and commercial manufacturers world-wide. For additional information, visit the division’s website: www.cyclodex.com Recent News |
Company InformationCyclo Therapeutics, Inc. Issue Type: Common Stock Management TeamN. Scott Fine Jeffrey L. Tate, Ph.D. Sharon H. Hrynkow, Ph.D. Joshua Fine Michael Lisjak |
|
Investor RelationsSitrick and Company |
Transfer AgentVStock Transfer, LLC |
AuditorsWithumSmith+Brown, PC |
